Covid-19 roundup: Pfiz­er, BioN­Tech kick off EUA dance for teen bi­va­lent shot; Re­port de­tails slow US boost­er roll­out

3 years ago
Coronavirus

Ru­bik's Cube still not solved at Mereo as ac­tivist in­vestor re­jects biotech's of­fer for board seats

3 years ago
People

With con­sumer health be­hind it, GSK taps As­traZeneca vet Julie Brown as CFO for R&D-fo­cused fu­ture

3 years ago
People

Liv­er-fo­cused start­up nabs $115M in ex­change for rare dis­ease drug roy­al­ties

3 years ago
Financing

They’re go­ing for it: David Liu’s pre­clin­i­cal biotech shoots for a (maybe $200M) IPO

3 years ago
Financing

The End­points 11; blue­bird's $3M gene ther­a­py; Bio­gen tout new neu­ro da­ta; Harsh re­views for can­cer drugs; and more

3 years ago
Weekly

As­traZeneca, Mer­ck cull one Lyn­parza in­di­ca­tion in heav­i­ly pre­treat­ed ovar­i­an can­cer pa­tients

3 years ago
R&D

Fu­ji­film con­tin­ues CD­MO ex­pan­sion, break­ing ground on $435M UK site

3 years ago
Manufacturing

An­oth­er Cipla site lands a Form 483 over clean­ing is­sues and QC con­trols

3 years ago
Pharma
FDA+

FDA ad­comm takes down Se­cu­ra Bio's leukemia drug af­ter fi­nal tri­al re­sults show po­ten­tial OS detri­ment

3 years ago
FDA+

Should SCO­TUS hear Am­gen's Repatha case? So­lic­i­tor gen­er­al says no

3 years ago
Pharma
Law

The End­points 11: Fire­side chat with No­bel Prize lau­re­ate Phil Sharp

3 years ago

EMA warns of short­ages of two Boehringer heart drugs due to a spike in de­mand

3 years ago
Pharma
Manufacturing

What can phar­ma do to re­build trust in sci­ence? For­mer Pres­i­dent Oba­ma has some ideas — and oth­er thoughts for the ...

3 years ago
Pharma
Marketing

WHO-backed Afrigen plans a charge to­ward the clin­ic with Africa's first Covid-19 vac­cine

3 years ago
Coronavirus

Klick Health gath­ers biotech and phar­ma lu­mi­nar­ies to dis­cuss in­dus­try in­no­va­tions, in­vest­ments and fu­ture

3 years ago
Pharma
Marketing

Covid-19 roundup: Mod­er­na sends in EUA for bi­va­lent teen boost­er; US trim­ming Pfiz­er/BioN­Tech do­na­tions

3 years ago
Coronavirus

Pre­ci­sion on­col­o­gy biotech agrees to $72M cash in­fu­sion as it seeks to in­crease rev­enue

3 years ago
Financing

Pfiz­er and Sang­amo re-open PhI­II of he­mo­phil­ia A gene ther­a­py; AEON head­ed to PhI­II

3 years ago
News Briefing

FDA's out­side ex­perts vote in fa­vor of Fer­ring's fe­cal trans­plant for C. dif­fi­cile, set­ting the stage for Seres

3 years ago
Pharma
FDA+

An­ti­bod­ies once act­ed on­ly as pro­tein block­ers. Now, sci­en­tists are find­ing new ways to make them pro­tein de­stroy­ers

3 years ago
Discovery

As­traZeneca shuts the PhI­II door for Ion­is' PC­SK9 drug de­spite pos­i­tive PhI­Ib

3 years ago
R&D

Amid mas­sive turnover, Agios hires Bio­gen alum as new CFO; Schol­ar Rock, Ever­est Med­i­cines lead the big CEO pa­rade

3 years ago
Peer Review

ODAC gives a big thumbs-down to On­copep­tides' dan­gling ac­cel­er­at­ed ap­proval in mul­ti­ple myelo­ma

3 years ago
FDA+
First page Previous page 456457458459460461462 Next page Last page
A service from the Financial Times